Cambridge, United Kingdom · Founded 2019 · Privately Held (backing)
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. LoQus23 Therapeutics is based in Cambridge, United Kingdom and was founded in 2019. Its last known valuation is $61.4 million. It has raised $67.2 million.
Last price · $/share
—
Implied valuation
$61.4M
Total raised
$67.2M
Last round
—
Team — not yet on record
No current team members for LoQus23 Therapeutics are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of LoQus23 Therapeutics with a free account
·Watch LoQus23 Therapeutics: the Monday email on marks, rounds and moves
